SMC ‘yes’ to first immunotherapy combination for skin cancer patients
Allows adult patients with advanced melanoma to receive first-line treatment with the potentially life-extending combination therapy of Opdivo (nivolumab) and Yervoy (ipilimumab) on the NHS in Scotland.
Bristol-Myers Squibb (BMS) has announced that the Scottish Medicines Consortium (SMC) has issued guidance which will allow adult patients with advanced (unresectable or metastatic) melanoma to receive first-line treatment with the potentially life-extending combination therapy of Opdivo q (nivolumab) + Yervoy (ipilimumab) on the NHS in Scotland.
The SMC’s decision was primarily supported by data from a Phase III study (Checkmate -067), which showed that patients treated with the combination therapy saw their cancer kept at bay for almost four times longer than those treated with ipilimumab alone (progression free survival was 11.5 months with the combination vs. 2.9 months with ipilimumab alone.
“We are delighted that skin cancer patients in Scotland will now be able to access this innovative combination of immunotherapies for the first time,” said Gill Nuttall, Melanoma UK. “Advanced melanoma is an aggressive disease and the prognosis is often poor. The availability of the nivolumab plus ipilimumab combination therapy on the NHS is therefore an important new addition in the fight to extend survival. We hope this new therapy will give many patients more valuable time with their families and loved ones.”
Safety assessments showed Grade 3-4 adverse events (AEs) occurred in 55% of patients treated with the combination vs. 27% and 16% of those treated with ipilimumab and nivolumab monotherapy, respectively. AEs were generally managed using established guidelines and the majority of grade 3/4 AEs resolved with the use of immune modulating medication at a median of 5 weeks. Patients with poor prognostic factors had a similar safety profile to the entire study population.
In addition to the positive recommendation for nivolumab in combination with ipilimumab for skin cancer patients, the SMC has also issued guidance which will deny Scottish NHS patients with previously treated advanced kidney cancer the option of treatment with nivolumab. The SMC submission for kidney cancer included data from a pivotal Phase III trial showing that patients who received nivolumab as a second-line treatment lived an average of 5.4 months longer than those treated with a current standard therapy (everolimus).“We are very happy for Scottish melanoma patients and their families who will now have access to the nivolumab plus ipilimumab combination therapy for melanoma,” said Ben Hickey, General Manager, UK and Ireland, “Our aim is to ensure all eligible patients in the UK are able to receive treatment with our innovative medicines and we will continue to work with the SMC to find a way forward for kidney cancer patients in Scotland.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance